Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Employee Ownership for Financial Health

Stocks are one of the most commonly used investment options, with 58 percent of Americans reporting they owned some form of stocks in 2022, according to Gallup. But what about owning stock in the company you work for, or employee stock ownership plans (ESOPs)? There are just under 14 million participants in the U.S., which…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from FinFit on MarketScale.

Share

Stocks are one of the most commonly used investment options, with 58 percent of Americans reporting they owned some form of stocks in 2022, according to Gallup. But what about owning stock in the company you work for, or employee stock ownership plans (ESOPs)? There are just under 14 million participants in the U.S., which amounts to around 4 percent of the U.S. population. But recently, there has been more interest in companies promoting ESOP to their employees.

What are the drivers behind this trend, and how do ESOPs influence employee dedication to a company as well as the financial health of both employees and the company?

In this episode of SECURE by FinFit, host Charles Lattimer, Chief Innovation Officer at FinFit, interviewed Jon Burg, Partner, Infinite Equity, Inc., to discuss equity and employee compensation and how it impacts employee behaviors and financial resiliency.

Lattimer and Burg also discussed…

  1. The benefits of employee ownership to the company and the future of their financial health
  2. Leadership team viewpoints when it comes to the expense of stock option matches and 401K contributions
  3. How employee ownership fits into the ESG initiative

“When we think about ownership culture, that’s not something you can truly measure. It’s more of a mindset. You know you’re successful when the employees really embody those values and spirits and the corporate objectives. They’re thinking like owners and you can see it in really little ways,” Burg stated.

Jon Burg is a former pension actuary who has more than two decades of experience in employee equity compensation programs. Burg is Partner at Infinite Equity, Inc. Some of his past work experiences include positions as Partner at Aon, Vice President at JPMorgan Compensation and Benefit Strategies, and Consultant at the former Chicago Consulting Actuaries. Burg earned his BS in Mathematics from the University of Washington.

FinFit

Part of this channel

FinFit

Executive conversations on building a financially resilient workforce.

Visit the channel →

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512